

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN TURKEY

Çağlayan B., Firidin A., Yıldırım N.¹, Tatar M.², Eşsiz M.³

¹UCB Pharma, Istanbul, Turkey, ²Hacettepe University, Ankara, Turkey, ³Polar Sağlık Health Economics & Policy, Ankara, Turkey

INTRODUCTION

•Axial spondyloarthritis (axSpA) is a rheumatic disease that includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).

•Certolizumab pegol (CZP) is a tumour necrosis factor (TNF)- α antagonist indicated for the treatment of axSpA.

OBJECTIVE

•The objective of this study was to assess the cost-effectiveness of CZP in axSpA patients in Turkey compared to other anti-TNFs and standard care.

METHODOLOGY

•A Markov model was developed to estimate costs and outcomes associated with CZP and comparator treatment.

•The study was undertaken from the Turkish health care payer perspective.

•The primary endpoint was ASAS20 response.

•A mixed treatment comparison was undertaken to compare CZP with adalimumab, infliximab, etanercept and golimumab for the treatment of AS.

•Similar comparisons were made for the treatment of nr-axSpA, where CZP was compared with adalimumab.

•Costs and effects were evaluated over a lifetime and discounted at 3%.

•Results were presented as incremental cost/Life Years Gained.


•One-way and probabilistic sensitivity analyses were also conducted.

INPUTS OF THE MODEL

•Resource utilization data were obtained from expert clinical opinion and included physician visits, monitoring costs, and others.

•Unit costs were taken from the Social Security Institution's 2015 official price list.

Figure 1: Model Diagram



This study was supported by UCB Pharma

Table 1. ICERs for AS treatment comparing CZT to other ANTI-TNF and standart care (12 week)

	ADA	IFX	ETA	GOL	Standart Care
Incremental Cost	-22.436,56	-48.336,84	-18.459,82	-22.020,83	47.843,76
Life Year Gained	0,000	0,000	0,000	0,000	0,000
ICER	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Dominated

ADA: Adalimumab, IFX: Infliximab, ETA: Etanercept, GOL: Golimumab

Table 2: ICERs for AS treatment comparing CZT to other ANTI-TNF and standart care (24 week)

	ADA	IFX	ETA	GOL	Standart Care
Incremental Cost	-4.955,72	-41.599,72	-5.150,75	-5.022,52	56.346,04
Life Year Gained	0,000	0,000	0,000	0,000	0,000
ICER	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Cheaper, equally effective	Dominated

Table 3: ICERs for nr-akSpA treatment comparing CZT to other ANTI-TNFs and standart care

	ADA	Standart Care
Incremental Cost	-2.396,26	48.187,94
Life Year Gained	0,000	0,000
ICER	Dominant	Dominated

RESULTS

•The base case analysis for AS, showed that CZP was equally effective and less costly compared to adalimumab, infliximab, etanercept and golimumab.

•In nr-axSpA, CZP dominated adalimumab. Sensitivity analyses confirmed the robustness of the model.

CONCLUSION

•The present analyses showed that CZP is a cost-effective alternative therapy for the treatment axSpA patients in Turkey.